Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities

[1]  R. Collins,et al.  FK 506 ( Tacrolimus ) Monotherapy for Prevention of Graft-Versus-Host Disease After Histocompatible Sibling Allogeneic Bone Marrow Transplantation , 2002 .

[2]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[3]  A. Nademanee,et al.  Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation , 1998 .

[4]  J. Wingard,et al.  The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  A. Monaco,et al.  Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. , 1997, Transplantation.

[6]  J. Fay,et al.  FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.

[7]  R. Wiesner,et al.  A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. , 1996, Transplantation.

[8]  H. Deeg,et al.  Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation , 1996 .

[9]  J. Alexander,et al.  Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. , 1996, Transplantation.

[10]  R. Stratta,et al.  A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. , 1996, Transplantation.

[11]  J. Byrnes,et al.  Thrombotic microangiopathic syndromes after bone marrow transplantation. , 1996, Cancer investigation.

[12]  H. Deeg,et al.  Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. , 1996, Blood.

[13]  J. Wingard,et al.  Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. , 1995, Bone marrow transplantation.

[14]  H. Dohy,et al.  FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. , 1995, Bone marrow transplantation.

[15]  R A Nash,et al.  Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. , 1995, Blood.

[16]  J. Reyes,et al.  FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. , 1995, Bone marrow transplantation.

[17]  W. Bechstein,et al.  Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation. , 1995, Clinical transplantation.

[18]  A. Monaco,et al.  Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). , 1995, Transplantation.

[19]  D. Neuberg,et al.  Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. , 1994, Blood.

[20]  European Cooperative Study Group.  Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection , 1994, The Lancet.

[21]  T. Starzl,et al.  FK506 “RESCUE” FOR RESISTANT REJECTION OF RENAL ALLOGRAFTS UNDER PRIMARY CYCLOSPORINE IMMUNOSUPPRESSION1 , 1994, Transplantation.

[22]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[23]  G. Klintmalm,et al.  Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. , 1993, Transplantation proceedings.

[24]  J. Dubernard,et al.  Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation , 1993 .

[25]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[26]  T. Naoe,et al.  Haemolytic uraemic syndrome during FK506 therapy , 1992, The Lancet.

[27]  A. Kanamaru,et al.  Phase II study of FK 506 for allogeneic bone marrow transplantation. , 1991, Transplantation proceedings.

[28]  R. Gascoyne,et al.  Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. , 1991, Bone marrow transplantation.

[29]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[30]  J. Gribben,et al.  Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. , 1991, Blood.

[31]  M. Pepe,et al.  Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. , 1991, Transplantation.

[32]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[33]  G. Herzig,et al.  Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation , 1991, Journal of clinical apheresis.

[34]  R. Storb,et al.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. , 1990, Human immunology.

[35]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[36]  K. Sullivan,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.

[37]  T. Starzl,et al.  TREATMENT OF CYCLOSPORIN-INDUCED HAEMOLYTIC URAEMIC SYNDROME WITH FK506 , 1989, The Lancet.

[38]  W. Lehmacher,et al.  Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. , 1989, Blood.

[39]  H. Prentice,et al.  Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation? , 1988, Bone marrow transplantation.

[40]  S. Sallan,et al.  Intravascular hemolysis and renal insufficiency after bone marrow transplantation. , 1988, Blood.

[41]  G. Forbes,et al.  Central Nervous System Toxicity after Liver Transplantation , 1987 .

[42]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[43]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[44]  K. Sullivan,et al.  ASSOCIATION BETWEEN CYCLOSPORIN NEUROTOXICITY AND HYPOMAGNESAEMIA , 1984, The Lancet.

[45]  J. Biggs,et al.  Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation. , 1984, The New England journal of medicine.

[46]  K. Atkinson,et al.  Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes , 1983, British journal of haematology.

[47]  R. Verwilghen,et al.  CYCLOSPORIN, METHYLPREDNISOLONE, AND CONVULSIONS , 1982, The Lancet.

[48]  E. Gordon-Smith,et al.  CYCLOSPORIN A, METHYLPREDNISOLONE, AND CONVULSIONS , 1982, The Lancet.

[49]  H. Deeg,et al.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. , 1981, The New England journal of medicine.

[50]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[51]  H. F. Woods,et al.  AGE-DEPENDENT SENSITIVITY TO SALICYLATE , 1975, The Lancet.

[52]  H. Mahler.  HEALTH-A DEMYSTIFICATION OF MEDICAL TECHNOLOGY , 1975, The Lancet.

[53]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.